Profound Medical Corp. Closes $36 Million Registered Direct Offering; Expects to Complete Subsequent Private Placement On or Before December 30th

Executive Summary

• Profound Medical Corp. closed a registered direct offering of 5,142,870 common shares at $7.00 per share, generating approximately $36 million in gross proceeds before fees.
• The equity raise was led by healthcare‑focused investors and existing shareholders; no warrants were issued.
• Net proceeds are earmarked for sales & marketing expansion, working capital, R&D, strategic transactions, and general corporate purposes.

Key Details

• Offering Size: 5,142,870 common shares
• Purchase Price: $7.00 per share
• Gross Proceeds: ~$36 million (pre‑fees & expenses)
• Structure: Straightforward equity investment; no warrant coverage.
• Lead Investors: Healthcare‑dedicated investors and existing shareholders.
• Placement Agent: Konik Capital Partners, LLC (division of T.R. Winston and Company, LLC).
• Use of Proceeds: Expansion of sales & marketing, working capital, research & development, strategic transactions, general corporate purposes.
• Regulatory Filing: Offering made pursuant to an effective Form S‑3 shelf registration (File No. 333-291516) declared effective on December 4, 2025. Prospectus supplement filed with the SEC is publicly available.
• Concurrent Private Placement: Company plans a private placement to Canadian purchasers, expected to close on or before December 30, 2025, subject to TSX conditional approval; U.S. investors excluded.

Notable Quotes

(No direct quotes were included in the release.)